Bio-Rad Laboratories, Inc.

NYSE:BIO Stock Report

Market Cap: US$7.7b

Bio-Rad Laboratories Future Growth

Future criteria checks 0/6

Bio-Rad Laboratories's earnings are forecast to decline at 2.4% per annum while its annual revenue is expected to grow at 2.3% per year. EPS is expected to decline by 2.5% per annum. Return on equity is forecast to be 3.2% in 3 years.

Key information

-2.4%

Earnings growth rate

-2.49%

EPS growth rate

Life Sciences earnings growth13.5%
Revenue growth rate2.3%
Future return on equity3.24%
Analyst coverage

Good

Last updated02 Sep 2025

Recent future growth updates

Analysts Are Updating Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Estimates After Its Second-Quarter Results

Aug 03
Analysts Are Updating Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Estimates After Its Second-Quarter Results

Recent updates

Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause

Aug 07

Analysts Are Updating Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Estimates After Its Second-Quarter Results

Aug 03
Analysts Are Updating Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Estimates After Its Second-Quarter Results

We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Jul 14
We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
User avatar

Acquisition And Droplet Digital PCR Will Advance Oncology Diagnostics

Bio-Rad's efforts in digital PCR technology and strategic acquisitions aim to expand applications and bolster revenue through oncology diagnostics and rare mutation detection.

Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Apr 10
Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?

Mar 18
Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?

Some Confidence Is Lacking In Bio-Rad Laboratories, Inc. (NYSE:BIO) As Shares Slide 28%

Feb 28
Some Confidence Is Lacking In Bio-Rad Laboratories, Inc. (NYSE:BIO) As Shares Slide 28%

Is There An Opportunity With Bio-Rad Laboratories, Inc.'s (NYSE:BIO) 39% Undervaluation?

Feb 18
Is There An Opportunity With Bio-Rad Laboratories, Inc.'s (NYSE:BIO) 39% Undervaluation?

Bio-Rad: Uncertainties And Conservatism Continue To Hold Stock Back From Its Full Potential

Jan 29

Getting In Cheap On Bio-Rad Laboratories, Inc. (NYSE:BIO) Is Unlikely

Jan 06
Getting In Cheap On Bio-Rad Laboratories, Inc. (NYSE:BIO) Is Unlikely

Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?

Dec 16
Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?

Why Bio-Rad Laboratories Is Overvalued: A Fundamental And DCF Analysis

Nov 25

Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Potentially Undervalued?

Nov 25
Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Potentially Undervalued?

A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Nov 04
A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad Laboratories: Overvalued Given Current Growth Prospects

Sep 23

We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Sep 08
We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Bio-Rad: Economics Unsupportive With Capital Valued 70 Cents On The Dollar

Jul 14

Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker

Apr 14

Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance

Oct 25

Bio-Rad: A Cash Flow Returns On Investments Analysis

Aug 10

Bio-Rad Labs reports Q4 2022 results

Feb 16

Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals

Jan 04

Earnings and Revenue Growth Forecasts

NYSE:BIO - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20272,755224N/AN/A5
12/31/20262,671209N/AN/A6
12/31/20252,595207N/AN/A6
6/30/20252,554319348534N/A
3/31/20252,541-2,164332515N/A
12/31/20242,567-1,844266455N/A
9/30/20242,580-779224412N/A
6/30/20242,563-1,326177346N/A
3/31/20242,605-322185347N/A
12/31/20232,671-637218375N/A
9/30/20232,720-159223374N/A
6/30/20232,769-428153287N/A
3/31/20232,779-191125242N/A
12/31/20222,802-3,62780194N/A
9/30/20222,805-6,021152286N/A
6/30/20222,871-1,930364505N/A
3/31/20222,896-91459606N/A
12/31/20212,9234,254536670N/A
9/30/20212,9806,659670783N/A
6/30/20212,8804,045590689N/A
3/31/20212,7014,098533626N/A
12/31/20202,5463,814480585N/A
9/30/20202,3803,521378450N/A
6/30/20202,2941,947323414N/A
3/31/20202,3291,579383478N/A
12/31/20192,3121,759368458N/A
9/30/20192,304377272403N/A
6/30/20192,289905251366N/A
3/31/20192,292574N/A288N/A
12/31/20182,289366N/A285N/A
9/30/20182,2941,277N/A250N/A
6/30/20182,2831,030N/A216N/A
3/31/20182,212767N/A201N/A
12/31/20172,160122N/A104N/A
9/30/20172,11017N/A130N/A
6/30/20172,08513N/A153N/A
3/31/20172,09726N/A168N/A
12/31/20162,06826N/A216N/A
9/30/20162,06798N/A157N/A
6/30/20162,02897N/A188N/A
3/31/20162,018108N/A149N/A
12/31/20152,019109N/A186N/A
9/30/20152,047103N/A190N/A
6/30/20152,10897N/A199N/A
3/31/20152,139100N/A237N/A
12/31/20142,17589N/A273N/A
9/30/20142,17980N/A304N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIO's earnings are forecast to decline over the next 3 years (-2.4% per year).

Earnings vs Market: BIO's earnings are forecast to decline over the next 3 years (-2.4% per year).

High Growth Earnings: BIO's earnings are forecast to decline over the next 3 years.

Revenue vs Market: BIO's revenue (2.3% per year) is forecast to grow slower than the US market (9.4% per year).

High Growth Revenue: BIO's revenue (2.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BIO's Return on Equity is forecast to be low in 3 years time (3.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/08 03:43
End of Day Share Price 2025/09/05 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bio-Rad Laboratories, Inc. is covered by 25 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Jon WoodBofA Global Research
Yuan ZhiB. Riley Securities, Inc.